Komori
Nippon Shinyaku (4516) · FactR&D expenses and ratio increased

High R&D expenses relative to net sales

First written in FY2016. 3 of 35 entries say "Restated". Latest entry: FY2026.

35entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2018-Q1 – FY20262016: 320162017: 420172018: 320182019: 420192020: 420202021: 420212022: 320222023: 420232024: 320242025: 220252026: 12026
Same theme, other companies
Ongoing disclosure of the R&D expense-to-sales ratioA theme 2 companies write about · 0 as a headwind · 1 as a tailwind

1 other company's latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026R&D expenses and ratio increasedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥36,713 million, representing 21.5% of revenue.」

    R&D expenses rose from ¥34,341 million in the previous fiscal year to ¥36,713 million, while the ratio to revenue increased from 21.4% to 21.5%.
  2. FY2026-H1R&D expenses and the ratio declined.Annual report

    「R&D expenses for the current interim consolidated accounting period were ¥14,637 million, representing 18.4% of revenue.」

    R&D expenses declined from ¥16,732 million in the same period of the previous year to ¥14,637 million, while the ratio to revenue fell from 21.1% to 18.4%.
  3. FY2025R&D expenses increased, while the ratio was flat.Annual report

    「R&D expenses for the current consolidated fiscal year were ¥34,341 million, representing 21.4% of revenue.」

    R&D expenses increased from ¥31,676 million in the previous fiscal year, while the ratio to revenue was 21.4%, unchanged from the previous fiscal year.
  4. FY2025-H1R&D expenses and ratio increasedAnnual report

    「R&D expenses for the current interim consolidated accounting period were ¥16,732 million, representing 21.1% of revenue.」

    R&D expenses increased from ¥12,517 million in the same period of the previous year to ¥16,732 million, while the ratio to revenue rose from 17.1% to 21.1%.
  5. FY2024R&D expenses and ratio increasedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥31,676 million, representing 21.4% of revenue.」

    R&D expenses rose from ¥24,135 million in the previous fiscal year to ¥31,676 million, while the ratio to revenue increased from 16.7% to 21.4%.
  6. FY2024-Q3R&D expenses and ratio increasedAnnual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥19,500 million, representing 17.3% of revenue.」

    R&D expenses rose from ¥15,135 million in the same period of the previous year to ¥19,500 million, while the ratio to revenue increased from 13.8% to 17.3%.
  7. FY2024-Q2R&D expenses and ratio increasedAnnual report

    「R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥12,517 million, representing 17.1% of revenue.」

    R&D expenses rose from ¥9,691 million in the same period of the previous year to ¥12,517 million, while the ratio to revenue increased from 13.6% to 17.1%.
  8. FY2024-Q1R&D expenses and ratio increasedAnnual report

    「R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥5,852 million, representing 15.8% of revenue.」

    R&D expenses increased from ¥4,738 million in the same period of the previous year, when they represented 13.3% of revenue, to ¥5,852 million and 15.8%, respectively.
  9. FY2023R&D expenses and ratio increasedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥24,135 million, representing 16.7% of revenue.」

    R&D expenses increased from ¥22,863 million in the previous fiscal year to ¥24,135 million, and the ratio to revenue was 16.7%.
  10. FY2023-Q3R&D expenses and the ratio declined year on year.Annual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥15,135 million, representing 13.8% of revenue.」

    R&D expenses declined from ¥15,541 million in the same period of the previous year to ¥15,135 million, while the ratio to revenue fell from 14.8% to 13.8%.
  11. FY2023-Q2R&D expenses and the ratio declined year on year.Annual report

    「R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥9,691 million, representing 13.6% of revenue.」

    R&D expenses declined from ¥10,117 million in the same period of the previous year, when they represented 14.1% of revenue, to ¥9,691 million and 13.6%, respectively.
  12. FY2023-Q1R&D expenses as a percentage of net sales increased year on yearAnnual report

    「R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥4,738 million, representing 13.3% of revenue.」

    The R&D expense ratio rose year on year, with 13.3% of revenue allocated to R&D expenses.
  13. FY2022-Q3R&D expenses and the ratio rose.Annual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥15,706 million, representing 14.8% of net sales.」

    R&D expenses rose from ¥11,459 million in the same period of the previous year to ¥15,706 million, while the ratio to net sales increased from 12.5% to 14.8%.
  14. FY2022-Q2R&D expenses and the ratio rose.Annual report

    「R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥10,005 million, representing 14.0% of net sales.」

    R&D expenses rose from ¥7,659 million in the same period of the previous year to ¥10,005 million, while the ratio to net sales increased from 13.2% to 14.0%.
  15. FY2022-Q1R&D expenses increased, while the ratio declined.Annual report

    「R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥3,699 million, representing 9.0% of net sales.」

    R&D expenses increased from ¥2,836 million in the same period of the previous year to ¥3,699 million, while the ratio to net sales declined from 9.5% to 9.0%.
  16. FY2021R&D expenses and the ratio rose.Annual report

    「R&D expenses for the current consolidated fiscal year were ¥16,104 million, representing 13.2% of net sales.」

    R&D expenses increased from ¥13,994 million in the previous fiscal year, when they represented 12.0% of net sales, to ¥16,104 million and 13.2%, respectively.
  17. FY2021-Q3R&D expenses increased, while the ratio was flat.Annual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥11,459 million, representing 12.5% of net sales.」

    R&D expenses increased from ¥11,011 million in the same period of the previous year, while the ratio to net sales was unchanged at 12.5%.
  18. FY2021-Q2R&D expenses and the ratio rose.Annual report

    「R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥7,659 million, representing 13.2% of net sales.」

    R&D expenses rose from ¥6,567 million in the same period of the previous year to ¥7,659 million, while the ratio to net sales increased from 11.4% to 13.2%.
  19. FY2021-Q1R&D expenses and the ratio declined.Annual report

    「R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,836 million, representing 9.5% of net sales.」

    R&D expenses declined from ¥2,969 million in the same period of the previous year, when they represented 10.1% of net sales, to ¥2,836 million and 9.5%, respectively.
  20. FY2020R&D expenses and the ratio declined.Annual report

    「R&D expenses for the current consolidated fiscal year were ¥13,994 million, representing 12.0% of net sales.」

    R&D expenses declined from ¥16,701 million in the previous fiscal year, when they represented 14.6% of net sales, and both the amount and the ratio to net sales fell.
  21. FY2020-Q3The R&D expense ratio declined.Annual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥11,011 million, representing 12.5% of net sales.」

    The R&D expense ratio declined from 13.5% in the same period of the previous year to 12.5%, while R&D expenses fell from ¥11,727 million to ¥11,011 million.
  22. FY2020-Q2The R&D expense ratio declined.Annual report

    「R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥6,567 million, representing 11.4% of net sales.」

    The R&D expense ratio declined from 14.7% in the same period of the previous year to 11.4%, while R&D expenses fell from ¥7,864 million to ¥6,567 million.
  23. FY2020-Q1R&D expenses as a percentage of net sales increased year on yearAnnual report

    「R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,969 million, representing 10.1% of net sales.」

    The R&D expense ratio rose from 9.1% in the same period of the previous year to 10.1%, while R&D expenses increased from ¥2,202 million to ¥2,969 million.
  24. FY2019R&D expenses as a percentage of net sales increasedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥16,701 million, representing 14.6% of net sales.」

    R&D expenses increased from ¥13,221 million in the previous fiscal year to ¥16,701 million, and the ratio to net sales also rose.
  25. FY2019-Q3R&D expenses as a percentage of net sales increasedAnnual report

    「R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥11,727 million, representing 13.5% of net sales.」

    The R&D expense ratio rose from 11.6% in the same period of the previous year to 13.5%, while R&D expenses increased from ¥9,051 million to ¥11,727 million.
  26. FY2019-Q2R&D expenses as a percentage of net sales increasedAnnual report

    「R&D expenses for the first six months of the current consolidated cumulative period were ¥7,864 million, representing 14.7% of net sales.」

    The R&D expense ratio rose from 12.6% in the same period of the previous year to 14.7%, while R&D expenses increased from ¥6,270 million to ¥7,864 million.
  27. FY2019-Q1R&D expenses as a percentage of net sales increased year on yearAnnual report

    「R&D expenses for the first quarter of the current consolidated cumulative period were ¥3,065 million, representing 11.0% of net sales.」

    The R&D expense ratio rose from 9.1% in the same period of the previous year to 11.0%, while R&D expenses increased from ¥2,202 million to ¥3,065 million.
  28. FY2018-Q3R&D expenses as a percentage of net sales increased year on yearAnnual report

    「R&D expenses for the first nine months of the current consolidated cumulative period were ¥9,051 million, representing 11.6% of net sales.」

    The R&D expense ratio rose from 10.3% in the same period of the previous year to 11.6%, while R&D expenses increased from ¥7,850 million to ¥9,051 million.
  29. FY2018-Q2R&D expenses as a percentage of net sales increased year on yearAnnual report

    「R&D expenses for the first six months of the current consolidated cumulative period were ¥6,270 million, representing 12.6% of net sales.」

    The R&D expense ratio rose from 11.4% in the same period of the previous year to 12.6%, while R&D expenses increased from ¥5,052 million to ¥6,270 million.
  30. FY2018-Q1R&D expenses as a percentage of net sales declined year on yearAnnual report

    「R&D expenses for the first quarter of the current consolidated cumulative period were ¥2,202 million, representing 9.1% of net sales.」

    R&D expenses were ¥2,202 million, or 9.1% of net sales, down in both amount and ratio from ¥2,521 million and 10.6%, respectively, in the same period of the previous year.
  31. FY2017AdvancedAnnual report

    「R&D expenses for the consolidated fiscal year were ¥14,903 million, representing 15.1% of net sales.」

    R&D expenses increased from ¥9,739 million in the previous fiscal year, and the ratio to net sales also rose from 11.6%.
  32. FY2017-Q3RestatedAnnual report

    「R&D expenses for the first nine months of the current consolidated cumulative period were ¥7,850 million, representing 10.3% of net sales.」

    R&D expenses accounted for 10.3% of net sales, with high levels of R&D investment continuing.
  33. FY2017-Q2RestatedAnnual report

    「R&D expenses for the first six months of the current consolidated cumulative period were ¥5,052 million, representing 11.4% of net sales.」

    R&D expenses accounted for 11.4% of net sales for the cumulative quarter, with high levels of R&D investment continuing.
  34. FY2017-Q1RestatedAnnual report

    「R&D expenses for the first quarter of the current consolidated cumulative period were ¥2,521 million, representing 10.6% of net sales.」

    R&D expenses accounted for 10.6% of net sales in the quarter as well.
  35. FY2016First statedAnnual report

    「R&D expenses for the consolidated fiscal year were ¥9,739 million, representing 11.6% of net sales.」

    R&D expenses were ¥9,424 million in the pharmaceuticals business and ¥314 million in the functional foods business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.